ClinicalTrials.gg

Program

Levonorgestrel

Also written as “Levonorgestrel/Ethinyl Estradiol”, “levonorgestrel” and “ethinyl estradiol and levonorgestrel; exenatide”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Menorrhagia · Premenstrual Syndrome · Endometriosis · Endometrial Hyperplasia, led by 8 companies.

Furthest: phase 4, since Oct 26, 200640 company-led studies, 3 open or runningNext primary completion: May 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer180 open or runningphase 4since Oct 26, 2006Sep 13, 2005none ahead
Pfizer90 open or runningphase 3since Aug 8, 2005Aug 8, 2005none ahead
Teva Pharmaceutical Industries50 open or runningphase 3since Sep 12, 2005Sep 12, 2005none ahead
Grünenthal30 open or runningphase 1since Nov 12, 2019Nov 12, 2019none ahead
Agile Therapeutics20 open or runningphase 2since Nov 29, 2010Nov 29, 2010none ahead
chemo-research11 open or runningphase 3since Jul 20, 2026Jul 20, 2026Dec 2030phase 3 · NCT07734155
corium-innovations-inc11 open or runningphase 1since Aug 26, 2026Aug 26, 2026May 31, 2027phase 1 · NCT07794150
nextfertility11 open or runningno phasesince Feb 26, 2024Feb 26, 2024none ahead

Also a collaborator on its studies: Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 26 studies since Aug 8, 2005.

  1. Jun 18, 2012Phase 2 study in HealthyAgile Therapeutics · NCT01623466 · 36 enrolled
  2. Jul 28, 2014Phase 2 study in EndometriosisBayer · NCT02203331 · 319 enrolled · United States, Austria, Belgium and more
  3. Mar 26, 2015Phase 3 study in ContraceptionBayer · NCT02403401 · 1,471 enrolled · United States, Japan
  4. Sep 8, 2015Phase 1 study in EndometriosisBayer · NCT02545452 · 52 enrolled · Germany
  5. Dec 5, 2016Phase 3 study in MenorrhagiaBayer · NCT02985541 · 364 enrolled · United States
  6. Mar 3, 2017Phase 3 study in ContraceptionBayer · NCT03074045 · 145 enrolled · Russian Federation
  7. Sep 5, 2018Phase 1 study in Healthy FemalesPfizer · NCT03662516 · 17 enrolled · United States
  8. Nov 12, 2019Grünenthal's first study: phase 1 study in BioequivalenceNew to GrünenthalGrünenthal · NCT04194905 · 10 enrolled · Chile
  9. Jan 13, 2020Phase 1 study in BioequivalenceGrünenthal · NCT04230070 · 30 enrolled · Chile
  10. Feb 25, 2022Phase 1 study in Therapeutic EquivalencyGrünenthal · NCT05282940 · 36 enrolled · India
  11. Feb 26, 2024nextfertility's first study: no phase study in Infertility, FemaleNew to nextfertilitynextfertility · NCT06304220 · 210 planned · Spain
  12. Mar 21, 2025Phase 3 study in Endometrial HyperplasiaBayer · NCT06904274 · United States, Canada, China
  13. Jul 20, 2026chemo-research's first study: phase 3 study in Contraception BehaviorNew to chemo-researchchemo-research · NCT07734155 · 1,600 planned
  14. Aug 26, 2026corium-innovations-inc's first study: phase 1 study in MenopauseNew to corium-innovations-inccorium-innovations-inc · NCT07794150 · 250 planned · United States, India

Ahead

  1. May 31, 2027Primary completion: phase 1 study in Menopausecorium-innovations-inc · NCT07794150
  2. Dec 2030Primary completion: phase 3 study in Contraception Behaviorchemo-research · NCT07734155

TargetBeta

PGR →read by rule
“Progesterone receptor agonist”ChEMBL 37, by rule

Other programs on PGR

ProgramCompanyFurthest phaseStudies
drospirenoneruleestetraphase 420
Megestrol AcetateruleChangchun GeneScience Pharmaceuticalphase 419
Medroxyprogesterone AcetaterulePfizerphase 411
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Utrogestanrulecalla-lily-clinical-care-ltdphase 11

Studies

All 40 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07794150Menopause · United States, India1Recruitingcorium-innovations-incMay 31, 2027250
NCT07734155Contraception Behavior3Not yet recruitingchemo-researchDec 20301,600
NCT06904274Endometrial Hyperplasia · United States, Canada, China3WithdrawnBayerJun 17, 20260
NCT06304220Infertility, Female · Spain–Not yet recruitingnextfertilitySep 2024210
NCT05282940Therapeutic Equivalency · India1CompletedGrünenthalMar 15, 202236
NCT04230070Bioequivalence · Chile1CompletedGrünenthalOct 31, 202030
NCT04194905Bioequivalence · Chile1CompletedGrünenthalNov 21, 202010
NCT03662516Healthy Females · United States1CompletedPfizerJan 19, 201917
NCT03074045Contraception · Russian Federation3CompletedBayerSep 3, 2018145
NCT02985541Menorrhagia · United States3CompletedBayerMay 28, 2021364
NCT02545452Endometriosis · Germany1CompletedBayerMar 14, 201652
NCT02403401Contraception · United States, Japan3CompletedBayerJul 7, 20161,471
NCT02203331Endometriosis · United States, Austria, Belgium and more2CompletedBayerOct 24, 2016319
NCT01623466Healthy2CompletedAgile TherapeuticsSep 201236
NCT01434160Contraception · Austria, Belgium, Denmark and more3CompletedBayerJun 2013304
NCT01397097Contraception · Australia, Finland, France and more3CompletedBayerJun 2013766
NCT01250210Ovulation Suppression · United States2CompletedAgile TherapeuticsFeb 2008123
NCT01254292Contraception · United States, Austria, Belgium and more3CompletedBayerJan 8, 2013567
NCT01096498Contraception · Mexico1CompletedBayerMar 200924
NCT01096485Contraception · Mexico1CompletedBayerMar 200924
NCT01073904Contraceptives, Postcoital · Mexico1CompletedBayerSep 200932
NCT00996580Pregnancy Prevention · United States3CompletedTeva Pharmaceutical IndustriesSep 20113,597
NCT00924560Bone Mineral Density · United States2CompletedTeva Pharmaceutical IndustriesAug 20121,361
NCT00884260Contraception · Australia, China, Korea, Republic of3CompletedBayerJun 2013918
NCT00777556Emergency Contraception · United States3CompletedTeva Pharmaceutical IndustriesDec 2010343
NCT00696202Medicated Intrauterine Devices · France4CompletedBayer199
NCT00498784Contraception · France4CompletedBayerOct 2007141
NCT00447863Contraception1WithdrawnPfizer0
NCT00394771Metrorrhagia · United States2CompletedTeva Pharmaceutical IndustriesMar 2008567
NCT00393198Menorrhagia · Finland, France, Ireland and more4CompletedBayerOct 2012204
NCT00360490Menorrhagia · United States, Argentina, Brazil and more3CompletedBayerJun 2008165
NCT00319163Healthy · United States1CompletedPfizerNov 200626
NCT00254189Ovulation2CompletedPfizer60
NCT00248963Oral Contraceptive3CompletedPfizer600
NCT00245921Contraception3CompletedPfizerOct 20052,000
NCT00195559Premenstrual Syndrome · Argentina, Brazil, Chile and more3CompletedPfizer526
NCT00185380Contraception · Finland, Hungary, Norway and more2CompletedBayerDec 2008742
NCT00196326Contraception · United States3CompletedTeva Pharmaceutical IndustriesJun 20072,235
NCT00161681Premenstrual Syndrome · United States3CompletedPfizerAug 2006200
NCT00128934Menstruation Disturbances · United States, Canada3CompletedPfizer744

How it is read

Names in the registry

  • “Levonorgestrel/Ethinyl Estradiol”, 5 entries
  • “levonorgestrel”, 5 entries
  • “Levonorgestrel”, 3 entries
  • “ethinyl estradiol and levonorgestrel; exenatide”, 3 entries
  • “Ethinyl Estradiol + Levonorgestrel”, 2 entries

Codes read as this program: BAY865028.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.